DESTINY-PanTumor02

• Research type

  Research Study

• Full title

  A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

• IRAS ID

  1003450

• Contact name

  Mark Woods

• Sponsor organisation

  AstraZeneca AB

• Eudract number

  2020-001574-29

• Clinicaltrials.gov Identifier

  NCT04482309

• Research summary

  DESTINY-PanTumor 02 is an open-label, multi center, multi cohort study that will investigate the safety and efficacy of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2 expressing tumours; these tumour cohorts include urothelial (bladder) cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumours.
  Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favourable risk benefit profile in selected HER2-expressing solid tumours.

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  21/NW/0116

• Date of REC Opinion

  18 May 2021

• REC opinion

  Further Information Favourable Opinion